Tom Allaway

UPDATES

Following the National Institute of Health and Care Excellence's (NICE) recommendation of relugolix with estradiol and norethisterone acetate in final draft guidance, around 4500 women with uterine...

Updates

The National Institute of Health and Care Excellence (NICE) has recommended an innovative and potentially life-extending drug for treating people with a specific gene mutation of advanced...

UPDATES

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tixagevimab/cilgavimab (Evusheld), a new monoclonal antibody combination, for COVID-19 pre-exposure prophylaxis, or...

New medication tackles obesity

Drug updates: March

Around 400 patients with advanced breast cancer will now be able to benefit from a new treatment after the National Institute of Health and Care Excellence (NICE) published final draft guidance...

A case of decency

Hello and happy new year from the Journal of Prescribing Practice (JPrP). I'm sure for many that sentiment feels like a stretch this year. Last year we had the hope of the COVID-19 vaccination program...

Drug updates: January

Around 1500 people in England with spinal muscular atrophy (SMA), a rare genetic condition, will benefit from a new medicine after The National Institute for Health and Care Excellence (NICE) released...

Drug updates: December

Draft guidance, published on the 18 November, is the first time NICE has made recommendations about the use of an HIV treatment since these came under NICE's remit in 2019. It is estimated that...

Prescribing e-cigarettes

Drug Updates: October

Ronapreve, a combination of two monoclonal antibodies, is the first targeted medicine developed for COVID-19 to receive marketing authorisation from the Medicines and Healthcare products Regulatory...

Overcoming vaccine hesitancy

I'm sure you have all read the more outlandish and outright illogical arguments for not having the COVID-19 vaccine, and these don't really warrant touching upon in a healthcare journal, but there are...

Drug Updates: September

Following new draft guidance from the National Institute for Health and Care Excellence (NICE), midostaurin (Rydapt, Novartis) has been recommended for the treatment of advanced systemic mastocytosis...

Drug Updates: August

Enzalutamide plus androgen deprivation therapy (ADT) is recommended by NICE, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults.

Take Pride in your progress

In a year of news about COVID-19, it is easy for a genuinely exciting development like the topic of this month's editorial to get lost in the relentless news cycle of late. I don't think I myself have...

Updates: July 2021

On 10 June, the National Institute for Health and Care Excellence (NICE) published new final guidance that has recommended several new treatment options for around 25 000 people with moderate...